Venus Remedies

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE411B01019
  • NSEID: VENUSREM
  • BSEID: 526953
INR
1,488.10
-12.65 (-0.84%)
BSENSE

Nov 20

BSE+NSE Vol: 34.95 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Part of MojoOne Strategy
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Syncom Formul.
Venus Remedies
NGL Fine Chem
Bharat Parenter.
Windlas Biotech
Beta Drugs Ltd
Amrutanjan Healt
Hester Bios
Panacea Biotec
Dishman Carbogen
Accent Microcell
Why is Venus Remedies Ltd ?
1
Company has a low Debt to Equity ratio (avg) at 0 times
2
The company has declared Positive results for the last 8 consecutive quarters
  • NET SALES(Latest six months) At Rs 397.62 cr has Grown at 20.52%
  • ROCE(HY) Highest at 22.14%
  • DEBTORS TURNOVER RATIO(HY) Highest at 9.55 times
3
Stock is technically in a Mildly Bullish range
  • Multiple factors for the stock are Bullish like MACD, Bollinger Band and KST
4
With ROE of 17.3, it has a Attractive valuation with a 2.8 Price to Book Value
  • The stock is trading at a fair value compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 115.40%, its profits have risen by 94.7% ; the PEG ratio of the company is 0.2
5
Despite the size of the company, domestic mutual funds hold only 0% of the company
  • Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
6
Market Beating Performance
  • The stock has generated a return of 115.40% in the last 1 year, much higher than market (BSE500) returns of 0.37%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Venus Remedies should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Venus Remedies for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Venus Remedies
115.4%
2.10
54.84%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
8.16%
EBIT Growth (5y)
36.43%
EBIT to Interest (avg)
57.65
Debt to EBITDA (avg)
0.48
Net Debt to Equity (avg)
-0.11
Sales to Capital Employed (avg)
1.14
Tax Ratio
23.26%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
3.88%
ROCE (avg)
11.18%
ROE (avg)
8.34%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
16
Industry P/E
40
Price to Book Value
2.82
EV to EBIT
12.87
EV to EBITDA
10.73
EV to Capital Employed
3.04
EV to Sales
2.28
PEG Ratio
0.17
Dividend Yield
0.67%
ROCE (Latest)
23.64%
ROE (Latest)
17.27%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

18What is working for the Company
NET SALES(Latest six months)

At Rs 397.62 cr has Grown at 20.52%

ROCE(HY)

Highest at 22.14%

DEBTORS TURNOVER RATIO(HY)

Highest at 9.55 times

PBT LESS OI(Q)

At Rs 32.96 cr has Grown at 33.01%

PAT(Q)

At Rs 25.65 cr has Grown at 27.4%

-1What is not working for the Company
CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 22.07 cr

Loading Valuation Snapshot...
Here's what is working for Venus Remedies
Net Sales - Latest six months
At Rs 397.62 cr has Grown at 20.52%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 32.96 cr has Grown at 33.01%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 25.65 cr has Grown at 27.4%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Debtors Turnover Ratio- Half Yearly
Highest at 9.55 times
in the last five half yearly periods
MOJO Watch
Company has been able to settle its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Venus Remedies
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 22.07 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents